Status:

COMPLETED

dnaJ Peptide for Relieving Rheumatoid Arthritis

Lead Sponsor:

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18-85 years

Phase:

PHASE2

Brief Summary

A small protein called dnaJ peptide may help people with rheumatoid arthritis (RA) by preventing their immune system cells from attacking their own tissues. The purpose of this study is to determine i...

Detailed Description

Immune modulation is a promising new approach for the treatment of RA. Studies have shown that immune cells in the joints of people in the early stages of RA react strongly against dnaJ peptides from ...

Eligibility Criteria

Inclusion Criteria:

  • Active rheumatoid arthritis as defined by the revised American College of Rheumatology (ACR) 1987 criteria. Evidence of active disease will be based on at least six swollen or nine tender joints.
  • Diagnosis of rheumatoid arthritis of less than 5 years
  • Reactivity to dnaJ
  • Agree to use acceptable methods of contraception
  • Able to understand and sign informed consent

Exclusion Criteria:

  • Patients taking more 7.5 mg of prednisone or disease modifying agents other than hydrochloroquine or sulfasalazine (i.e., gold, penicillamine, azathioprine, cyclophosphamide, methotrexate, cyclosporine, or anti-TNF agents)
  • Serum creatinine greater than 1.5 mg/dl
  • SGOT less than SGPT
  • Alkaline phosphatase greater than 2 times age/sex adjusted normal values
  • Hematocrit of less than 30
  • Platelets less than 130,000
  • History of lymphoma
  • Any active malignancy or cancer requiring treatment in the last 5 years, except for nonmelanoma skin cancers and carcinoma of the cervix in situ
  • Medical or psychiatric condition or active serious infection
  • Pregnant or breastfeeding

Key Trial Info

Start Date :

September 1 1999

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2004

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT00000435

Start Date

September 1 1999

End Date

September 1 2004

Last Update

July 31 2007

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

University of Arizona Health Sciences Center

Tucson, Arizona, United States, 85724-5093

2

University of California, Irvine Medical Center

Orange, California, United States, 92868

3

Stanford University

Palo Alto, California, United States, 94305

4

Denver Arthritis Center

Denver, Colorado, United States, 80230